These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12180721)

  • 1. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D; Smolen JS
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
    J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M; Schettler JD; Fries JF
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.